Regeneron Pharmaceuticals Stock Forecast, Price & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 10.6% and is now trading at $514.05.
View which stocks have been most impacted by COVID-19.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals.

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $8.36 EPS for the quarter, missing the Zacks' consensus estimate of $9.52 by $1.16. The biopharmaceutical company earned $2.29 billion during the quarter, compared to analyst estimates of $2.09 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The business's quarterly revenue was up 31.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.67 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has authorized a share repurchase program on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 2.9% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its shares are undervalued.

24 equities research analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $429.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $628.52 in the next year. This suggests a possible upside of 22.3% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 2,330,000 shares, an increase of 13.7% from the September 30th total of 2,050,000 shares. Based on an average daily trading volume, of 857,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.3% of the shares of the company are short sold.
View Regeneron Pharmaceuticals' Short Interest.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX), Ionis Pharmaceuticals (IONS) and Amicus Therapeutics (FOLD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.20%), State Street Corp (4.38%), Nuveen Asset Management LLC (1.53%), Sands Capital Management LLC (0.80%), California Public Employees Retirement System (0.78%) and UBS Asset Management Americas Inc. (0.56%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Nuveen Asset Management LLC, Polar Capital LLP, Polar Capital LLP, Sustainable Growth Advisers LP, DNB Asset Management AS, LSV Asset Management, and Neuberger Berman Group LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, AQR Capital Management LLC, Candriam Luxembourg S.C.A., Swiss National Bank, UBS Asset Management Americas Inc., Voloridge Investment Management LLC, KBC Group NV, and Wells Fargo & Company MN.
View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $514.05.

Regeneron Pharmaceuticals has a market capitalization of $54.85 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,142 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]